Purdue Pharma L.p.

Euro-celtique S.a.

Purdue Pharmaceuticals L.p.

The P.f. Laboratories, Inc.

Euroceltigue, S.a.

Mundipharma Ag

Mundipharma Gmbh

Mundipharma Pharmaceuticals Bv

Mundipharma Farmaceutica Lda

Mundipharma Gesmbh

Mundipharma Ab

Mundipharma Pharmaceuticals Sl

Mundipharma Cva

Norpharma A/s

Mundipharma Pharmaceuticals S.r.l.

Benjamin Oshlack

Curtis Wright

Christopher D Breder

Hua-Pin Huang

Mark Chasin

John K Masselink

Alfred P Tonelli

Frank Pedi, Jr

J David Haddox

Derek Allan Prater

John J Minogue

Richard S Sackler

Paul D Goldenheim

Robert F Kaiko

Robert D Colucci

JDavid Haddox

James William McGinity

Dileep Bhagwat

Roland Bodmeier

Glenn Van Buskirk

Richard Mannion

Philip Goliber

Stewart Thomas Leslie

Thinnayam Naganathan Krishnamurthy

Andrew Darke

Anthony E Carpanzano

Stephen A Howard

Mark Alfonso

Ihor Shevchuk

Rampurna Gullapalli

Lino Tavares

Geraldine Marcenyac

David Sackler

Vijay Vashi

Lane Gehrlein

Joseph V Zirlis

Frank C Pedi, Jr

Bruce E Reidenberg

Rampurna Prasad Gullapalli

Seth Levy

Ronald Greenbaum

Chris Breder

James P Cassidy

Robert Francis Kaiko

Derek Prater

David J Haddox

Stephan Howard

Lane Gerhlein

Mark A Alfonso

John Josepf Minongue

John Joseph Minogue

Meredith Machonis

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Pharmaceutical formulation containing gelling agent

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.

Oxycodone formulations

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Tamper resistant oral opioid agonist formulations

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C/Cratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

Controlled release hydrocodone formulations

Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.

Pharmaceutical products

Methods of manufacturing oral dosage forms

Growing community of inventors

Boca Raton, FL, United States of America

Benjamin Oshlack